A Cross-Sectional Analysis of Funding Sources of Dermatologic Clinical Trials: Supplemental Tables

Introduction:
The National Institutes of Health (NIH) is the largest public funding source for medical research, yet funding for dermatology research has decreased by 24% in recent decades. This has prompted investigators to explore alternative funding sources.1,2 This study examines funding and topic trends for dermatologic clinical trials.

Methods:
A comprehensive list of trials completed between 2000-2023 was extracted from ClinicalTrials.gov. Funding sources were classified as Federal, Industry, Network, Individual, NIH, non-NIH governmental funding, and Other. Chi-square analysis was conducted using SPSS to explore relationships between funding sources, topics, and years, with a significance at p<0.05.

Results:
A total of 2,603 trials were analyzed, revealing a peak in funding in 2018 with 223 trials, followed by a sharp decline, with only 33 trials funded in 2023. Industry was the dominant funding source, followed by NIH and Other sources. Significant shifts in funding distribution were observed over time (χ²=182.353, p=0.002), with psoriasis, infectious diseases, and melanoma receiving the most funding. Industry funding prioritized psoriasis, cosmetics, and acne, while NIH funding concentrated on cutaneous oncology.

Discussion:
These findings emphasize the changing landscape of dermatologic research funding and highlight the need for continued investment in underfunded areas, particularly those with a high global disease burden.3,4 Rapid changes in governmental allocation of research funds will undoubtedly influence the future of dermatology.

Conclusion:
Recognizing funding trends highlights current disease priorities and reveals areas with growing needs. Dermatology societies must advocate for diverse funding sources to address emerging challenges and ensure equitable research across all dermatologic conditions.

引言：
美国国立卫生研究院（National Institutes of Health, NIH）是全球最大的医学研究公共资助机构，但近几十年来皮肤病学研究的资助经费已下降24%。这一现状促使研究者探索替代性资助来源[1,2]。本研究旨在分析皮肤病学临床试验的资助与主题趋势。

方法：
从临床试验数据库（ClinicalTrials.gov）中提取2000年至2023年完成的所有临床试验的完整列表。将资助来源划分为联邦资助、企业资助、合作网络资助、个人资助、NIH资助、非NIH政府资助及其他资助共七类。采用SPSS（Statistical Product and Service Solutions）进行卡方检验，以探究资助来源、研究主题与研究年份之间的关联，检验显著性阈值设定为p<0.05。

结果：
本研究共分析了2603项临床试验，结果显示资助规模在2018年达到峰值，当年共有223项试验获得资助，随后出现大幅下滑，2023年仅33项试验获得资助。企业资助为最主要的资助来源，其次为NIH资助及其他资助来源。研究观察到资助分布随时间发生显著变化（χ²=182.353，p=0.002），其中银屑病、传染病及黑色素瘤相关研究获得的资助最多。企业资助优先投向银屑病、化妆品相关皮肤病及痤疮领域，而NIH资助则集中于皮肤肿瘤学方向。

讨论：
本研究结果揭示了皮肤病学研究资助格局的动态变化，并强调了对资助不足领域持续投入的必要性，尤其是那些全球疾病负担较高的领域[3,4]。政府研究经费分配的快速变化无疑将对皮肤病学的未来发展产生深远影响。

结论：
明晰资助趋势有助于明确当前的疾病研究重点，并揭示出需求日益增长的研究领域。皮肤病学相关学会应倡导多元化的资助来源，以应对新兴挑战，并确保所有皮肤病相关研究均能获得公平的研究支持。